Bailard’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bailard’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,714	Closed	-$242K	–	704
2021 Q1	$242K	Sell	1,714 -1,800	-51%	-$271K	0.01%	594
2020 Q4	$457K	Buy	3,514 +14	+0.4%	+$1.87K	0.02%	348
2020 Q3	$510K	Hold	3,500	–	–	0.03%	279
2020 Q2	$518K	Hold	3,500	–	–	0.03%	267
2020 Q1	$381K	Hold	3,500	–	–	0.03%	270
2019 Q4	$403K	Hold	3,500	–	–	0.02%	355
2019 Q3	$281K	Hold	3,500	–	–	0.02%	413
2019 Q2	$254K	Hold	3,500	–	–	0.02%	453
2019 Q1	$327K	Buy	+3,500	New	+$293K	0.02%	402
2018 Q1	–	Sell	-3,500	Closed	-$445K	–	476
2017 Q4	$445K	Buy	+3,500	New	+$440K	0.03%	325
2013 Q3	–	Sell	-49,550	Closed	-$1.54M	–	216
2013 Q2	$1.54M	Buy	+49,550	New	+$1.32M	0.28%	76

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bailard's ALNY Position: Q2 2021 in Review

Bailard sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2021, closing a stake of 1,714 shares — an estimated $242K sold.

Bailard first reported a position in ALNY in Q2 2013 and held it in 11 quarters. The position peaked at $1.54M in Q2 2013. 401 funds tracked by Wall St. Rank hold ALNY as of Q2 2021.

Bailard reported no remaining Alnylam Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Bailard sold 1,714 Alnylam Pharmaceuticals shares in Q2 2021, an estimated $242K.
Bailard first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Bailard's Alnylam Pharmaceuticals position peaked at $1.54M in Q2 2013.
401 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2021.

Based on Bailard's 13F filing for Q2 2021, filed 13 Aug 2021.